Profile data is unavailable for this security.
About the company
Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the development, manufacturing & sale of pharmaceutical products and services& trading of commodities and renting of properties. The Company manufactures and markets more than 200 pharmaceutical formulation products in various dosage forms, like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections and Dry Vial injections, Dry Syrups, Ointments and Inhalers. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Albendazole Oral Suspension USP 100mg, Cetirizine Oral Solution BP, Clotrimazole Cream USP, Compound Benzoic Acid Ointment BP, and others.
- Revenue in INR (TTM)3.29bn
- Net income in INR331.47m
- Incorporated1988
- Employees802.00
- LocationSyncom Formulations (India) Ltd207, Saket NagarINDORE 452018IndiaIND
- Phone+91 7 312700458
- Fax+91 7 313046872
- Websitehttps://syncomformulations.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lincoln Pharmaceuticals Ltd | 5.97bn | 966.39m | 12.49bn | 1.70k | 12.92 | 1.95 | 11.50 | 2.09 | 48.25 | 48.25 | 298.31 | 319.16 | 0.828 | 3.77 | 3.40 | 3,514,339.00 | 13.39 | 13.95 | 15.85 | 16.54 | 52.60 | 50.65 | 16.18 | 14.71 | 3.64 | 60.48 | 0.0021 | 3.44 | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Bliss GVS Pharma Ltd | 8.00bn | 634.20m | 12.71bn | 831.00 | 20.30 | 1.26 | 12.76 | 1.59 | 5.94 | 5.94 | 75.55 | 96.05 | 0.6454 | 3.10 | 1.98 | 9,628,987.00 | 5.80 | 6.46 | 7.04 | 8.22 | 50.26 | 43.91 | 8.99 | 9.92 | 3.74 | -- | 0.0825 | 7.92 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Remus Pharmaceuticals Ltd | 2.12bn | 215.37m | 13.88bn | 48.00 | 63.11 | 15.99 | 51.67 | 6.53 | 37.34 | 37.34 | 374.91 | 147.42 | 1.46 | 7.61 | 3.56 | 44,270,750.00 | 17.80 | -- | 44.48 | -- | 22.67 | -- | 12.22 | -- | 1.12 | 55.56 | 0.0997 | -- | 371.94 | -- | 153.29 | -- | -- | -- |
| Zota Health Care Ltd | 1.98bn | -242.34m | 14.72bn | 445.00 | -- | -- | 3,152.02 | 7.43 | -9.27 | -9.27 | 76.32 | -- | -- | -- | -- | 4,452,605.00 | -- | -1.38 | -- | -1.85 | 49.86 | 35.95 | -12.23 | -1.33 | -- | -2.87 | -- | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Jagsonpal Pharmaceuticals Ltd | 2.27bn | 243.00m | 15.29bn | 1.03k | 64.24 | 7.75 | 53.59 | 6.74 | 8.98 | 8.98 | 83.78 | 74.42 | 0.9703 | 5.13 | 9.92 | 2,213,181.00 | 10.39 | 10.95 | 12.40 | 13.29 | 58.16 | 58.13 | 10.71 | 9.21 | 2.60 | 32.84 | 0.0474 | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
| JG Chemicals Ltd | 7.57bn | 550.05m | 16.18bn | 56.00 | 27.97 | 3.71 | 25.94 | 2.14 | 14.77 | 14.77 | 202.34 | 111.33 | -- | -- | -- | 135,230,700.00 | -- | -- | -- | -- | 17.29 | -- | 7.56 | -- | 11.46 | -- | 0.0281 | -- | -14.90 | -- | -43.84 | -- | -- | -- |
| Sigachi Industries Ltd | 4.36bn | 660.99m | 16.60bn | 991.00 | 29.53 | 3.52 | 21.35 | 3.81 | 1.69 | 1.69 | 11.11 | 14.15 | 0.6266 | 3.01 | 3.27 | 4,396,491.00 | 9.36 | 14.77 | 13.25 | 19.57 | 50.50 | 50.30 | 14.93 | 14.92 | 1.39 | 6.47 | 0.2576 | 1.61 | 32.08 | 25.34 | 31.34 | 24.64 | 70.35 | -- |
| Syncom Formulations (India) Ltd | 3.29bn | 331.47m | 18.97bn | 802.00 | 49.71 | 6.05 | 49.28 | 5.76 | 0.406 | 0.406 | 3.49 | 3.34 | 0.8485 | 6.21 | 3.62 | 4,105,761.00 | 8.54 | 7.50 | 10.99 | 10.23 | 38.49 | 34.10 | 10.07 | 9.38 | 4.09 | 12.05 | 0.0435 | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
| Beta Drugs Ltd | 3.35bn | 410.00m | 19.37bn | 371.00 | 47.25 | 10.71 | 37.95 | 5.79 | 42.65 | 42.65 | 348.21 | 188.13 | 1.26 | 4.04 | 3.74 | 9,022,873.00 | 15.42 | 15.10 | 23.35 | 22.23 | 39.95 | 39.77 | 12.25 | 12.38 | 1.59 | 17.06 | 0.0953 | 0.00 | 30.21 | 35.01 | 18.62 | 35.29 | -10.89 | -- |
| Windlas Biotech Ltd | 6.96bn | 612.28m | 20.04bn | 1.15k | 32.84 | 4.25 | 24.79 | 2.88 | 29.20 | 29.20 | 331.88 | 225.63 | 1.06 | 6.07 | 4.43 | 6,028,180.00 | 9.30 | -- | 13.64 | -- | 37.52 | -- | 8.80 | -- | 1.61 | 30.61 | 0.0388 | -- | 22.97 | -- | 36.51 | -- | -- | -- |
| IOL Chemicals and Pharmaceuticals Ltd. | 20.72bn | 1.19bn | 20.62bn | 2.78k | 17.39 | -- | 11.15 | 0.9953 | 20.20 | 20.20 | 353.05 | -- | -- | -- | -- | 7,461,253.00 | -- | 14.91 | -- | 19.45 | 33.96 | 34.54 | 5.72 | 12.00 | -- | 10.06 | -- | 10.59 | -3.80 | 4.82 | -3.39 | -10.70 | 35.27 | -- |
| Hester Biosciences Ltd | 3.12bn | 234.69m | 20.73bn | 642.00 | 85.90 | 6.87 | 49.22 | 6.64 | 28.37 | 28.37 | 368.62 | 354.81 | 0.4617 | 1.22 | 3.23 | 4,862,882.00 | 3.89 | 6.15 | 4.91 | 7.69 | 71.13 | 66.64 | 8.42 | 12.83 | 1.22 | 2.85 | 0.4371 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
| Amrutanjan Health Care Ltd | 4.38bn | 475.20m | 20.92bn | 635.00 | 44.07 | 7.03 | 38.83 | 4.78 | 16.43 | 16.43 | 151.37 | 103.00 | 1.19 | 6.89 | 12.85 | 6,893,025.00 | 12.88 | 16.22 | 16.48 | 20.12 | 50.03 | 53.09 | 10.86 | 13.23 | 3.62 | 217.88 | 0.0074 | 18.95 | 10.96 | 10.71 | 12.90 | 12.46 | 26.93 | 16.43 |
| SMS Pharmaceuticals Ltd | 7.68bn | 593.38m | 21.20bn | 1.20k | 35.63 | 3.76 | 23.17 | 2.76 | 7.03 | 7.03 | 91.03 | 66.57 | 0.7278 | 1.81 | 4.18 | 6,420,048.00 | 5.55 | 5.43 | 8.40 | 7.33 | 30.10 | 33.30 | 7.62 | 7.87 | 0.7104 | 4.54 | 0.3361 | 6.17 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| Panacea Biotec Ltd | 5.50bn | -148.63m | 24.15bn | 1.15k | -- | 2.90 | 120.96 | 4.39 | -2.46 | -2.46 | 90.20 | 135.98 | 0.4374 | 1.10 | 7.87 | 4,799,546.00 | -1.22 | 10.26 | -1.65 | 16.53 | 63.28 | 50.27 | -2.79 | 24.87 | 1.03 | -13.78 | 0.0254 | 0.00 | 21.57 | 4.13 | 96.47 | -- | 74.65 | -- |
Data as of Nov 21 2024. Currency figures normalised to Syncom Formulations (India) Ltd's reporting currency: Indian Rupee INR
0.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 81.23k | 0.01% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Oct 2024 | 10.18k | 0.00% |
| Bandhan AMC Ltd.as of 31 Oct 2024 | 6.16k | 0.00% |
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
